Sorrento is expected to utilise its proprietary antibody library technology to identify fully human antibodies for the neutralisation of Staph-specific signaling peptides that control bacterial virulence. A research
Based on the successful data, the two parties continue to expect to partner with a worldwide or regional pharmaceutical company in order to commercialise the contraceptive gel. The
Traficet-EN (CCX282-B), a specific CCR9 antagonist with the potential to offer a new approach for the treatment of inflammatory bowel diseases, including crohn’s disease. Reportedly, the option also
The primary objective of the study is to investigate whether treatment with A0001 has a discernible impact on various functional, biochemical and subject/clinician-rated scales relevant in the treatment
Armodafinil tablets are the generic version of Nuvigil tablets, which are used to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea/hypnea syndrome, narcolepsy and
Patheon’s Bourgoin-Jallieu Operations, offers commercial scale manufacturing for a range of solid, semi-solid and liquid dosage forms. Packaging formats for solids include blisters (plastic and alu-cold formed) for
The study has achieved its primary clinical endpoint of a statistically improvement in International Prostate Symptom Score (IPSS) for patients treated with PRX302 versus subjects receiving placebo. In
The Phase 2a study has demonstrated proof-of-concept for DR Cysteamine, which is Raptor’s proprietary, delayed-release, enteric-coated microbead formulation of immediate release cysteamine bitartrate contained in a gelatin capsule.
The agreement allows Jubilant access to DiscoveRx PathHunter and cAMPHunter cell lines and proprietary EFC chemiluminescent detection technology to perform screening on behalf of Jubilant’s customers. The company
In the open-label, single-arm, Simon-design two-stage Phase II study entitled ‘Saphire’, Resminostat will be given orally at a dose of 600mg daily for five consecutive days, followed by
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.